Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of “Moderate Buy” by Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has received a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $14.00.

Several equities research analysts have issued reports on the company. Chardan Capital initiated coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th.

Insider Activity at Kalaris Therapeutics

In other Kalaris Therapeutics news, Director Srinivas Akkaraju acquired 479,847 shares of the stock in a transaction dated Thursday, December 18th. The stock was purchased at an average cost of $10.42 per share, for a total transaction of $5,000,005.74. Following the acquisition, the director owned 1,979,847 shares in the company, valued at $20,630,005.74. The trade was a 31.99% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 74.99% of the company’s stock.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of large investors have recently added to or reduced their stakes in KLRS. Nano Cap New Millennium Growth Fund L P bought a new stake in Kalaris Therapeutics in the fourth quarter worth $34,000. Barclays PLC purchased a new stake in Kalaris Therapeutics during the fourth quarter valued at about $51,000. Johnson Financial Group Inc. bought a new position in shares of Kalaris Therapeutics during the third quarter valued at about $58,000. Keel Point LLC bought a new position in shares of Kalaris Therapeutics during the fourth quarter valued at about $86,000. Finally, XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics in the fourth quarter worth about $92,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Stock Down 0.4%

KLRS opened at $9.17 on Friday. The stock has a market cap of $171.48 million, a PE ratio of -2.43 and a beta of -0.13. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The business’s fifty day simple moving average is $9.44 and its 200 day simple moving average is $7.11.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.